- Home
- EVRG vs UTHR Comparison
EVRG vs UTHR Comparison
Compare EVRG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRG
- UTHR
- Stock Information
- Founded
- EVRG 2017
- UTHR 1996
- Country
- EVRG United States
- UTHR United States
- Employees
- EVRG N/A
- UTHR N/A
- Industry
- EVRG Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- EVRG Utilities
- UTHR Health Care
- Exchange
- EVRG Nasdaq
- UTHR Nasdaq
- Market Cap
- EVRG 14.2B
- UTHR 15.5B
- IPO Year
- EVRG N/A
- UTHR 1999
- Fundamental
- Price
- EVRG $63.76
- UTHR $363.25
- Analyst Decision
- EVRG Buy
- UTHR Buy
- Analyst Count
- EVRG 7
- UTHR 14
- Target Price
- EVRG $62.57
- UTHR $370.86
- AVG Volume (30 Days)
- EVRG 1.9M
- UTHR 389.6K
- Earning Date
- EVRG 11-07-2024
- UTHR 10-30-2024
- Dividend Yield
- EVRG 4.03%
- UTHR N/A
- EPS Growth
- EVRG 25.01
- UTHR 25.10
- EPS
- EVRG 3.70
- UTHR 22.72
- Revenue
- EVRG $5,777,800,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- EVRG $7.40
- UTHR $26.32
- Revenue Next Year
- EVRG $2.28
- UTHR $10.37
- P/E Ratio
- EVRG $17.23
- UTHR $15.99
- Revenue Growth
- EVRG 3.18
- UTHR 25.04
- 52 Week Low
- EVRG $48.04
- UTHR $208.62
- 52 Week High
- EVRG $64.07
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- EVRG 65.62
- UTHR 42.87
- Support Level
- EVRG $62.71
- UTHR $396.52
- Resistance Level
- EVRG $64.07
- UTHR $417.82
- Average True Range (ATR)
- EVRG 1.07
- UTHR 12.41
- MACD
- EVRG 0.30
- UTHR -0.95
- Stochastic Oscillator
- EVRG 93.60
- UTHR 26.51
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.